对SI单位的时间.

T M Reynolds

Lancet (London, England)

|July 22, 1998

概括

No abstract available in PubMed .

相关概念视频

您也可能阅读

通过共同作者、期刊和引用图与本文相关的文章。

排序

Same author

Serum uric acid and new-onset hypertension: a possible therapeutic avenue?

Journal of human hypertension·2014

Same author

Targeted lipid treatment: decades of failure suggest new targets are in order.

International journal of clinical practice·2013

Same author

Prescribing high-dose lipid-lowering therapy early to avoid subsequent cardiovascular events: is this a cost-effective strategy?

European journal of preventive cardiology·2011

Same author

Implementing the national invasive cervical cancer audit: a local perspective.

BJOG : an international journal of obstetrics and gynaecology·2010

Same author

Comparison between transcutaneous bilirubinometry and total serum bilirubin measurements in preterm infants <35 weeks gestation.

Annals of clinical biochemistry·2009

Same author

Targeting treatment using calculated cardiovascular disease risk: effective? A shot in the dark? Or is it time to change the paradigm?

International journal of clinical practice·2009

Same journal

Assisted dying and the silencing of medicine's next generation.

Lancet (London, England)·2026

Same journal

Linguistic pragmatism: a woman with progressive abdominal pain in Thailand.

Lancet (London, England)·2026

Same journal

Medical compartmentalisation: a patient with chromosome 22q11.2 deletion syndrome in Japan.

Lancet (London, England)·2026

Same journal

[<sup>177</sup>Lu]Lu-edotreotide versus everolimus for gastroenteropancreatic neuroendocrine tumours (COMPETE): a phase 3, multicentre, randomised, open-label, superiority trial.

Lancet (London, England)·2026

Same journal

Research priorities for characterising Bundibugyo virus.

Lancet (London, England)·2026

Same journal

Rethinking treatment sequence in advanced gastroenteropancreatic neuroendocrine tumours.

Lancet (London, England)·2026

查看所有相关文章

相关实验视频

对SI单位的时间.

相关概念视频

Serum uric acid and new-onset hypertension: a possible therapeutic avenue?

Targeted lipid treatment: decades of failure suggest new targets are in order.

Prescribing high-dose lipid-lowering therapy early to avoid subsequent cardiovascular events: is this a cost-effective strategy?

Implementing the national invasive cervical cancer audit: a local perspective.

Comparison between transcutaneous bilirubinometry and total serum bilirubin measurements in preterm infants <35 weeks gestation.

Targeting treatment using calculated cardiovascular disease risk: effective? A shot in the dark? Or is it time to change the paradigm?

Assisted dying and the silencing of medicine's next generation.

Linguistic pragmatism: a woman with progressive abdominal pain in Thailand.

Medical compartmentalisation: a patient with chromosome 22q11.2 deletion syndrome in Japan.

[<sup>177</sup>Lu]Lu-edotreotide versus everolimus for gastroenteropancreatic neuroendocrine tumours (COMPETE): a phase 3, multicentre, randomised, open-label, superiority trial.

Research priorities for characterising Bundibugyo virus.

Rethinking treatment sequence in advanced gastroenteropancreatic neuroendocrine tumours.

相关实验视频

对SI单位的时间.

相关概念视频

Serum uric acid and new-onset hypertension: a possible therapeutic avenue?

Targeted lipid treatment: decades of failure suggest new targets are in order.

Prescribing high-dose lipid-lowering therapy early to avoid subsequent cardiovascular events: is this a cost-effective strategy?

Implementing the national invasive cervical cancer audit: a local perspective.

Comparison between transcutaneous bilirubinometry and total serum bilirubin measurements in preterm infants <35 weeks gestation.

Targeting treatment using calculated cardiovascular disease risk: effective? A shot in the dark? Or is it time to change the paradigm?

Assisted dying and the silencing of medicine's next generation.

Linguistic pragmatism: a woman with progressive abdominal pain in Thailand.

Medical compartmentalisation: a patient with chromosome 22q11.2 deletion syndrome in Japan.

[<sup>177</sup>Lu]Lu-edotreotide versus everolimus for gastroenteropancreatic neuroendocrine tumours (COMPETE): a phase 3, multicentre, randomised, open-label, superiority trial.

Research priorities for characterising Bundibugyo virus.

Rethinking treatment sequence in advanced gastroenteropancreatic neuroendocrine tumours.